A novel CRISPR system that suppresses genes related to adeno-associated virus (AAV) antibody production has been developed to prevent immunity against the gene therapy.
List view / Grid view
Filter the results
A new CRISPR technology has been created to understand mutations based on cytosine to guanine base changes and minimise unintended "off-target" mutations.
The novel CRISPR-CasΦ enzyme, isolated from bacteriophages, can target a wider range of genetic sequences, say the researchers.
Researchers reveal protospacer adjacent motif mutations (PAM sites) on the NRF2 gene of cancers could be used to guide CRISPR gene editing.
Researchers develop a knock-in mouse expressing human angiotensin-converting enzyme 2 (hACE2) to model SARS-CoV-2 infection for research and therapeutic or vaccine testing.
CRISPR screening utilises the power and precision of CRISPR-Cas9 gene editing to reveal and validate novel drug targets or to study the underlying causes of disease.
Researchers use CRISPR-Cas9 gene-editing to establish gangliosides are invoved in hepatitis A entering liver cells, revealing a potential drug target.
Induced pluripotent stem cells made to produce insulin and CRISPR, used to correct a genetic defect, cured Wolfram syndrome in mice.
Researchers have used CRISPR-Cas9 to screen the genome for possible targets that could be used in potential treatments for muscular dystrophy.
A study has shown that plasmids use type IV CRISPR-Cas against competing plasmids, leading the researchers to suggest the method as a novel way to tackle multi-drug resistant bacteria.
A new Cas13 RNA screen has been used to establish guide RNAs for the COVID-19 coronavirus and human RNA segments which could be used in vaccines, therapeutics and diagnostics.
Using a combination of Cas9 and Cas12a, Canadian researchers have enabled CRISPR methods to edit multiple genes at the same time.
A new systematic investigation on the role of solute carriers could lead to further insights into how the transporters affect the uptake and activity of drugs.
Researchers have shown that CRISPR-Cas3 can successfully attack C. difficile in vitro and in mice, by causing DNA damage to the pathogen.
A study has shown that altering amino acid residues in Cas9 to produce new variants can produce a vector with increased gene editing specificity.